A Randomized, Parallel-arm, Phase 2 Clinical Trial of the Combination of Glasdegib (PF-04449913) with Two Standard Decitabine Regimens for Older Patients with Poor-Risk Acute Myeloid Leukemia who are Unfit for or Refuse Intensive Chemotherapy
Myeloid and Monocytic Leukemia
What is the purpose of this trial?
This multi-center, randomized phase 2 study is designed to evaluate the complete remission (including complete remission with incomplete count recovery) rates of glasdegib in combination with either decitabine on a 5-day or 10-day schedule in patients with newly-diagnosed poor-risk AML who either refuse or are ineligible for intensive therapy.
- Trial withYale Cancer Center
- Start Date10/06/2019
- End Date12/20/2022
- Last Updated06/23/2020
- Study HIC#2000024738